enGene Therapeutics (ENGN) Assets (2022 - 2026)

enGene Therapeutics (ENGN) has 5 years of Assets data on file, last reported at $288.3 million in Q3 2026.

• For the quarter ending Q3 2026, Assets rose 17.42% year-over-year to $288.3 million; the trailing twelve-month figure through Jul 2026 stood at $288.3 million (up 17.42% YoY), and the FY2025 full-year result was $221.5 million, down 28.83% from the prior year.
• Assets was $288.3 million for Q3 2026 at enGene Therapeutics, down from $307.5 million in the prior quarter.
• In the past five years, Assets ranged from a high of $337.1 million in Q1 2026 to a low of $23.9 million in Q4 2022.
• A 5-year average of $231.4 million and a median of $266.9 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets surged 263.71% in 2023 and declined 28.83% in 2025, its largest moves.
• enGene Therapeutics' Assets stood at $23.9 million in 2022, then surged by 263.71% to $87.0 million in 2023, then soared by 257.84% to $311.2 million in 2024, then declined by 28.83% to $221.5 million in 2025, then surged by 30.19% to $288.3 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $288.3 million in Q3 2026, $307.5 million in Q2 2026, and $337.1 million in Q1 2026.